Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Rob Seitz"'
5
466 Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort
Autor: Douglas T. Ross, Andrea Dickey, Frank McMahon, Nicole S. Croteau, David R. Gandara, Kim McGregor, Rob Seitz, David L. Saltman, Tyler J. Nielsen, David R. Hout, Jeremy Spille, Heather Lockyer, Brock L. Schweitzer, Matthew Varga
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundLung cancer is the leading cause of cancer-related deaths worldwide. The advent of ICIs specifically targeting programmed cell death protein-1 (PD-1), or its ligand (PD-L1) represents a major therapeutic advance that is now included in stan
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7807f024395ed6dea09b51f4836e2c25
https://doaj.org/article/e817bad23cf54eeb8bc4dce9c0f11e9e
Zobrazit plný text záznamu
6
5 CD274 (PD-L1) gene expression and the 27-gene immuno-oncology (IO) assay are associated with efficacy to immune checkpoint inhibitor treated patients with non-small cell lung cancer (NSCLC)
Autor: Rob Seitz, Matthew Varga, Brock L. Schweitzer, Douglas T. Ross, Gregory Vidal, Tyler J. Nielsen, Kim McGregor
Publikováno v: Journal for ImmunoTherapy of Cancer. 9:A5-A5
BackgroundImmune checkpoint inhibitors (ICIs) have become standard of care in NSCLC. Programmed death ligand-1 (PD-L1) as measured by immunohistochemistry (IHC) is an accepted biomarker for predicting response but has many limitations. We previously
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::015f25573b9b9da55f67d2fe27e37373
https://doi.org/10.1136/jitc-2021-sitc2021.005
Zobrazit plný text záznamu
8
Abstract P6-08-04: Creation of a robust algorithm utilizing minimal gene sets normalized against a reference gene set to identify triple-negative breast cancer (TNBC) subtypes
Autor: Rob Seitz, Xi Chen, Jennifer A. Pietenpol, Brian Z. Ring, Stephan W. Morris, David R. Hout, Rebecca B Smith, Brian D. Lehmann
Publikováno v: Cancer Research. 75:P6-08
Introduction: Treatment of TNBC has been challenging due to the absence of well-characterized molecular targets and the heterogeneity of the disease. Using TNBC gene expression (GE) microarray profiles, the Pietenpol group molecularly binned the mali
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c5c936ec0b007ddf5089770f46f25e69
https://doi.org/10.1158/1538-7445.sabcs14-p6-08-04
Zobrazit plný text záznamu
10
Association of mesenchymal subtype with the presence of immune infiltrates in squamous cancer classifier
Autor: Rob Seitz, Daniel B. Bailey, David R. Hout, Brian Z. Ring
Publikováno v: Journal of Clinical Oncology. 35:e23073-e23073
e23073 Background: Lehmann and colleagues (Lehmann 2011) devised a classification system for triple negative breast cancer (TNBC) consisting of seven subtypes—IM, BL1, BL2, LAR, M, MSL, and UNS. Recent work has shown the IM group (characterized by
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b02da0d0b0102bd7bdc84c74f5db001
https://doi.org/10.1200/jco.2017.35.15_suppl.e23073
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje